ESR1 and breast carcinoma: Although new genomic studies provide a comprehensive catalog of genes that accumulate somatic point mutations and small additions (indels) in estrogen receptor-positive (ER+) breast cancer, significant uncertainties remain regarding how these newly discovered mutations relate to disease outcomes [6-8].